SLI
|
2 213,27
|
-12,35
|
-0,55 %
|
Analysen zu SLI-Werten
| 18.09.24 | Givaudan Underperform | Jefferies & Company Inc. | |
| 18.09.24 | Givaudan Buy | Goldman Sachs Group Inc. | |
| 18.09.24 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 18.09.24 | Zurich Insurance Neutral | Goldman Sachs Group Inc. | |
| 18.09.24 | Swiss Re Neutral | Goldman Sachs Group Inc. | |
| 17.09.24 | Givaudan Neutral | UBS AG | |
| 17.09.24 | Givaudan Neutral | UBS AG | |
| 17.09.24 | Givaudan Underperform | Jefferies & Company Inc. | |
| 17.09.24 | Givaudan Neutral | JP Morgan Chase & Co. | |
| 17.09.24 | Richemont Overweight | Barclays Capital | |
| 16.09.24 | Roche Sell | Goldman Sachs Group Inc. | |
| 16.09.24 | Roche Neutral | UBS AG | |
| 13.09.24 | Swiss Re Sector Perform | RBC Capital Markets | |
| 13.09.24 | Givaudan Neutral | UBS AG | |
| 13.09.24 | Roche Sell | Deutsche Bank AG | |
| 12.09.24 | Roche Sell | Goldman Sachs Group Inc. | |
| 11.09.24 | Novartis Buy | UBS AG | |
| 11.09.24 | ABB Neutral | JP Morgan Chase & Co. | |
| 10.09.24 | Roche Neutral | UBS AG | |
| 10.09.24 | Roche Sell | Goldman Sachs Group Inc. | |
| 10.09.24 | Richemont Outperform | Bernstein Research | |
| 10.09.24 | Roche Hold | Deutsche Bank AG |